ArticleBiomolecules2022
Bicalutamide Anticancer Activity Enhancement by Formulation of Soluble Inclusion Complexes with Cyclodextrins.
Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Modulation of Drug Release in Anticancer Therapy: Recent Advances, Challenges, and Emerging Drug Delivery Platforms.Pharmaceutics · 2026Review
- Chitosan-Based Thermosensitive Hydrogel Loaded with Quercetin Inclusion Compound for Accelerating Infectious Wound Healing.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Cyclodextrin-Based Formulations as a Promising Strategy to Overcome the Blood-Brain Barrier: Historical Overview and Prospects in Glioblastoma Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Conformational Landscape, Polymorphism, and Solid Forms Design of Bicalutamide: A Review.Molecules (Basel, Switzerland) · 2025Review
- Naringenin-Loaded Solid Lipid Nanoparticles: Physical-Chemical Characterization and In Vitro Antibacterial Activity.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Synthesis of mangiferin derivatives, complexes, and carriers as potential therapeutic candidates for cancer treatment: an update.Frontiers in pharmacology · 2025Review
- Study ofInternational journal of molecular sciences · 2024Article
- Influence of Solvent Polarity on the Conformer Ratio of Bicalutamide in Saturated Solutions: Insights from NOESY NMR Analysis and Quantum-Chemical Calculations.International journal of molecular sciences · 2024Article
- Rutin/Sulfobutylether-β-Cyclodextrin as a Promising Therapeutic Formulation for Ocular Infection.Pharmaceutics · 2024Article
- Intracranial Assessment of Androgen Receptor Antagonists in Mice Bearing Human Glioblastoma Implants.International journal of molecular sciences · 2023Article
- Article
- Preparation ofPharmaceutics · 2023Article
- Electrosprayed Core (Cellulose Acetate)-Shell (Polyvinylpyrrolidone) Nanoparticles for Smart Acetaminophen Delivery.Pharmaceutics · 2023Article
- Cyclodextrins as Multi-Functional Ingredients in Dentistry.Pharmaceutics · 2023Review
- Characterization and In Vivo Antiangiogenic Activity Evaluation of Morin-Based Cyclodextrin Inclusion Complexes.Pharmaceutics · 2023Article
- Nanomedicine Strategies for Targeting Tumor Stroma.Cancers · 2023Review
- Amphiphilic Cyclodextrin Nanoparticles as Delivery System for Idebenone: A Preformulation Study.Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bicalutamide (BCL) is a nonsteroidal antiandrogen drug that represents an alternative to castration in the treatment of prostate cancer, due to its relatively long half-life and tolerable side effects. However, it possesses a very low water solubility that can affect its oral bioavailability. In this work, we developed inclusion complexes of BCL with the highly soluble hydroxypropyl-β-cyclodextrin (HP-β-CyD) and sulfobutylether-β-cyclodextrin (SBE-β-CyD) to increase the water solubility and anticancer activity of BCL. The inclusion complexes were prepared using the freeze-drying method and were then characterized in a solid state via differential scanning calorimetry and X-ray analysis and in solution via phase-solubility studies and UV-vis and NMR spectroscopy. The BCL/HP-β-CyD and BCL/SBE-β-CyD inclusion complexes were amorphous and rapidly dissolved in water. Both the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.